LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

Author： Gao Jian-Jun  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.4, 2011-08, pp. : 574-582

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Synthesis and Activity Evaluation of a Bestatin Derivative (LYP) as an Aminopeptidase N Inhibitor

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 6, 2009-09 ,pp. : 420-423

Bentham Science Publishers

Access to resources Recommend Favorite

LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition

By  

Medicinal Chemistry, Vol. 7, Iss. 1, 2011-01 ,pp. : 32-36

Bentham Science Publishers

Access to resources Recommend Favorite

Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis

By  

Current Medicinal Chemistry, Vol. 14, Iss. 24, 2007-10 ,pp. : 2548-2553

Bentham Science Publishers

Access to resources Recommend Favorite

The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X 1 receptors

By Lambrecht G.   Rettinger J.   Baumert H.G.   Czeche S.   Damer S.   Ganso M.   Hildebrandt C.   Niebel B.   Spatz-Kumbel G.   Schmalzing G.   Mutschler E.  

European Journal of Pharmacology, Vol. 387, Iss. 3, 2000-01 ,pp. : 19-21

Elsevier

Access to resources Recommend Favorite

Bestatin as an Experimental Tool in Mammals

By  

Current Drug Metabolism, Vol. 2, Iss. 1, 2001-03 ,pp. : 67-85

Bentham Science Publishers

Access to resources Recommend Favorite